Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;11(3):232-244.
doi: 10.1159/000542568. Epub 2024 Nov 12.

Clinical Trials in Nail Psoriasis: Cross-Sectional Analysis of the Current State of Research

Amit Singal  1   2 , Nina Vijayvargiya  3 , Naeha Pathak  4   2 , Shari R Lipner  2
Affiliations

Clinical Trials in Nail Psoriasis: Cross-Sectional Analysis of the Current State of Research

Amit Singal et al. Skin Appendage Disord. 2025 Jun.

Abstract

Introduction: Nail involvement occurs in approximately 90% of patients with cutaneous psoriasis and in isolation in 5%-10% of patients. There is an unmet need for diagnostic and therapeutic algorithms for nail psoriasis (NP), partially due to limited number of clinical trials.

Methods: The ClinicalTrials.gov, the EU, the Australian New Zealand, and the World Health Organization International Clinical Trials Registries were queried for the term "nail psoriasis". Trial data characteristics were collected and analyzed.

Results: A total of 112 clinical trials were included, with mean trial length 46.7 weeks and mean number of participants 272.7. Medications were most often studied in 97 (86.6%) trials, followed by lasers in 7 (6.3%) trials. NP Severity Index score was the most often studied outcome measure in 91 (84.3%) trials, and only 56 (52.8%) trials assessed adverse events. Only 3 (2.83%) trials included children, and many clinical trials excluded patients aged 65+ and 85+. Results were posted for 46 (41.4%) trials with mean participant age 45.1 years, mean percentage of females of 38.3%, and 87.8% of participants being White.

Conclusion: Our findings highlight a need for clinical trials assessing efficacy and long-term therapeutic safety with a broad range of age-groups and increased representation of minorities and female patients.

Keywords: Clinical trials; Nail psoriasis; Outcome measures; Psoriasis; Treatment.

PubMed Disclaimer

Conflict of interest statement

Dr. Lipner has served as a consultant for Moberg Pharmaceuticals and Eli Lilly. The other authors have no conflict of interest to declare.

Similar articles

See all similar articles

References

    1. Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol. 2009;145(3):269–71. - PubMed
    1. de Vries ACQ, Bogaards NA, Hooft L, Velema M, Pasch M, Lebwohl M, et al. . Interventions for nail psoriasis. Cochrane Database Syst Rev. 2013(1):CD007633. - PMC - PubMed
    1. Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. . Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51. - PubMed
    1. Dennehy EB, Zhang L, Amato D, Goldblum O, Rich P. Ixekizumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: results from UNCOVER 3. J Drugs Dermatol. 2016;15(8):958–61. - PubMed
    1. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. . Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56. - PubMed

LinkOut - more resources